10-Q: Pluri Inc. Reports Q2 2024 Results: Revenue Growth and Cost Reductions Highlighted Amidst Ongoing Challenges

Pluri Inc. saw increased revenue and reduced expenses in the second quarter of fiscal year 2024, while navigating ongoing operational and financial challenges.

Summary

• Pluri Inc. reported its financial results for the quarter ended December 31, 2023, showing a net loss of $4.994 million, an improvement compared to the $8.254 million loss in the same quarter of the previous year.
• The company's revenue increased to $105,000 for the quarter, up from $2,000 in the same period last year, primarily due to services in CDMO and agtech.
• Research and development expenses decreased by 22% to $2.964 million, due to the completion of some clinical studies and cost reduction efforts.
• General and administrative expenses also decreased by 19% to $2.354 million, due to cost reduction measures and a temporary reduction in employee working hours.
• The company's cash and cash equivalents stood at $5.468 million as of December 31, 2023, with a working capital surplus of $27.722 million.
• Pluri has launched new business divisions, PluriCDMO for cell therapy manufacturing services and PluriAgtech for cell-based coffee production.
• The company is facing challenges including the need to maintain its Nasdaq listing and the impact of the ongoing conflict in Israel.

Sentiment

Score: 6

Explanation: The document presents a mixed picture. While there are positive developments such as revenue growth and cost reductions, the company still faces significant challenges, including ongoing losses, the risk of delisting, and geopolitical instability. The sentiment is cautiously optimistic, but with a clear awareness of the risks involved.

Positives

• The company experienced a substantial increase in revenue, driven by new business strategies in CDMO and agtech.
• Pluri has successfully reduced its operating expenses, including R&D and general and administrative costs.
• The company secured a significant contract with NIAID, which will support the development of its PLX-R18 cell therapy.
• Pluri has launched new business divisions, expanding its market reach and potential revenue streams.
• The company has a working capital surplus of $27.722 million, indicating a relatively healthy short-term financial position.

Negatives

• Pluri continues to operate at a net loss, although the loss has decreased compared to the previous year.
• The company has an accumulated deficit of $409.450 million, highlighting its long-term financial challenges.
• Pluri's cash position has decreased compared to the previous year, indicating a need for continued financial management.
• The company is facing the risk of delisting from Nasdaq if it does not regain compliance with the minimum bid price rule.
• The ongoing conflict in Israel could disrupt the company's operations and ability to raise capital.

Risks

• The company is at risk of being delisted from the Nasdaq Capital Market if its share price does not reach $1.00 for a minimum of 10 consecutive trading days by April 15, 2024.
• The ongoing armed conflict in Israel could disrupt operations, delay projects, and make it more difficult to raise capital.
• The company's insurance does not cover damages or losses resulting from the current war in Israel.
• Pluri is dependent on grants and contracts, and any reduction in such funding could adversely affect its financial results.
• The company has a significant accumulated deficit and may need to raise additional capital to support its operations and commercialization efforts.

Future Outlook

Pluri expects to generate revenue from collaborations and licensing agreements, but does not anticipate significant product sales in the next twelve months. The company may need to obtain additional liquidity resources to support its operations and commercialization efforts. Pluri believes it has sufficient cash to fund operations for at least the next twelve months.

Management Comments

• The company's management believes that its current resources, together with its existing operating plan, are sufficient to meet its obligations for at least twelve months.
• The company is continually looking for sources of funding, including non-diluting sources such as collaboration with other companies via licensing agreements, service agreements under our CDMO business, joint venture and partnerships, R&D contracts such as our agreement with the NIAID, research grants such as the IIA grants and the European Union grant, and sales of our common shares.

Industry Context

Pluri's expansion into CDMO and agtech reflects a broader trend in the biotechnology industry towards diversification and the application of cell-based technologies in various sectors. The company's focus on regenerative medicine and cell therapy aligns with the growing interest in these fields, but it faces competition from other companies developing similar technologies.

Comparison to Industry Standards

• Pluri's revenue growth, while significant on a percentage basis, is still relatively low compared to established biotechnology companies with commercialized products.
• The company's R&D spending is substantial, which is typical for a biotech company in the development phase, but it needs to demonstrate a clear path to commercialization to justify these expenses.
• Pluri's cash burn rate is a concern, and the company needs to secure additional funding or achieve profitability to ensure its long-term viability.
• Compared to companies like CRISPR Therapeutics and Editas Medicine, which are also focused on advanced cell-based technologies, Pluri is still in an earlier stage of development and commercialization.
• The company's reliance on grants and contracts is similar to many early-stage biotech companies, but it needs to diversify its revenue streams to reduce its dependence on external funding.

Management Changes

Stakeholder Impact

• Shareholders face the risk of delisting and potential loss of investment if the company does not regain compliance with Nasdaq listing requirements.
• Employees may be affected by cost reduction measures and potential disruptions due to the conflict in Israel.
• Customers and partners may benefit from the company's new business divisions and expanded service offerings.
• Creditors may be concerned about the company's ongoing losses and need for additional funding.

Next Steps

• The company intends to monitor the closing bid price of its common shares and may consider implementing options to regain compliance with the Nasdaq Listing Rules, including a reverse stock split.
• Pluri will continue to seek funding through various sources, including collaborations, licensing agreements, and grants.
• The company will continue to develop its cell-based technologies and expand its business divisions, including PluriCDMO and PluriAgtech.

Key Dates

Keywords

biotechnology, cell therapy, regenerative medicine, CDMO, agtech, financial results, cost reduction, Nasdaq, Israel, PLX cells